R Squared’s Zentalis Pharmaceuticals ZNTL Stock Holding History

R Squared’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,808	Closed	-$12.5K	–	732
2025 Q2	$12.5K	Buy	+10,808	New	+$14.3K	0.01%	454

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R Squared's ZNTL Position: Q3 2025 in Review

R Squared sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 10,808 shares — an estimated $12.5K sold.

R Squared first reported a position in ZNTL in Q2 2025 and held it in 1 quarter. The position peaked at $12.5K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

R Squared reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
R Squared sold 10,808 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $12.5K.
R Squared first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
R Squared's Zentalis Pharmaceuticals position peaked at $12.5K in Q2 2025.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.